论文部分内容阅读
目的:探讨重组人促红细胞生成素与铁剂联合治疗早产儿贫血的临床效果。方法:将74例早产贫血患儿随机分为观察组与对照组,各37例,对照组仅给予蛋白琥珀酸亚铁口服治疗,观察组在对照组基础上于患儿出生后第2周加用重组人促红细胞生成素(r Hu EPO)联合治疗。结果:观察组接受输血治疗1例(2.70%),对照组接受输血治疗9例(24.32%),组间比较以观察组输血治疗率明显降低(P<0.01);日龄7 d两组患者Hb、Hct、Ret 3项指标水平比较差异无统计学意义(P>0.05),而日龄21 d、42 d 3项指标水平组间比较均以观察组升高显著,与对照组比较差异有统计学意义(P<0.01)。结论:r Hu EPO与铁剂联合给药对早产儿贫血进行治疗的效果满意,建议将本联合用药方式在临床推广应用。
Objective: To investigate the clinical effect of recombinant human erythropoietin combined with iron on anemia in premature infants. Methods: 74 cases of premature anemia were randomly divided into observation group and control group, 37 cases in each group. The control group received oral administration of ferrous succinate only. On the basis of the control group, the observation group was given the second week after birth Treatment with recombinant human erythropoietin (r Hu EPO). Results: In the observation group, blood transfusion was treated in 1 case (2.70%), blood transfusion in the control group was 9 cases (24.32%), blood transfusion was significantly decreased in the observation group compared with the control group (P <0.01) Hb, Hct, Ret three indicators were no significant difference (P> 0.05), while the day of 21 d, 42 d three indicators were significantly increased in the observation group between the observation group, compared with the control group, there are differences Statistical significance (P <0.01). CONCLUSION: The combination of r-EPO with iron is satisfactory for the treatment of anemia in premature infants. It is suggested that the combination of r-EPO and iron should be promoted clinically.